Search
About Wistar Research & Facilities Education & Training Technology Transfer Ways of Giving News & Information
         
 


Overview
Licensing Opportunities
Technologies
Research Tools
Patents
By Inventor
Material Transfers
Guidelines for Inventors
Contact Us
     

Novel Influenza Vaccine

Inventor: Walter Gerhard and Laszlo Otvos

Tech ID: GW0301

Description:There is a critical unmet need for new influenza vaccines that are easily produced and that induce protective immunity which is broadly cross-reactive with current and future epidemic virus strains. The external M2 protein (M2e) is highly conserved among human influenza type A viruses and M2e-specific antibodies have the potential to provide broad protective immunity across influenza A strains. However, the natural M2 protein is poorly immunogenic so that individuals exposed to influenza virus or immunized with current vaccines do not develop these broadly-protective antibodies.

Wistar researchers have developed novel multiple antigenic peptide constructs (MAPs) that induce M2e-specific antibodies in vivo. These MAPs consist of M2e and helper T cell determinants that are covalently linked. Mice immunized intranasally with MAPs exhibited significant production of M2e-specific antibodies as well as decreased morbidity after influenza virus infection. These MAPs, administered independently or in conjunction with whole virus, may be useful for developing an effective broadly protective influenza vaccine.

Key Words: Vaccine, influenza, peptide vaccine.

Applications and Advantages: Any vaccine that produces broad immunity against influenza A would be a significant improvement over the current strain-specific vaccines that must be produced anew each year. Additionally, this vaccine would be produced synthetically, which is a major improvement over the current methods of growing influenza vaccine in fertilized eggs.

Intellectual Property Status: International patents are pending: Composition and Method for Preventing or Treating a Virus Infection. (WO04064784A2)

Licensing Opportunity:This technology is available for exclusive license.

Reference: Mozdzanowska, et al., Vaccine, 21, 2616-2626. 2003.

Contact:

Meryle J. Melnicoff
Director, Business Development
The Wistar Institute
3601 Spruce Street
Philadelphia, PA 19104
Phone: (215) 898-0049
Fax: (215) 573-2456
melnicoff@wistar.org

 


 

 

 

Contact Us

Meryle Melnicoff, PhD
Director, Business Development

Christopher Harold Croft
Administrative Coordinator

 

  © 2008 The Wistar Institute | Terms of Use